Literature DB >> 16246743

Intensity-modulated radiotherapy as the boost or salvage treatment of nasopharyngeal carcinoma: the appropriate parameters in the inverse planning and the effect of patient's anatomic factors on the planning results.

Ching-Yeh Hsiung1, Margie A Hunt, Ellen D Yorke, Chen-Shou Chui, Jason Hu, Jian-Ping Xiong, Clifton C Ling, Sing-Kai Lo, Chong-Jong Wang, Eng-Yen Huang, Howard I Amols.   

Abstract

The current study demonstrates that the large increase in normal tissue penalty often degrades target dose uniformity without a concomitant large improvement in normal tissue dose, especially in anatomically unfavorable patients. The excessively large normal tissue penalties do not improve treatment plans for patients having unfavorable geometry.

Entities:  

Mesh:

Year:  2005        PMID: 16246743     DOI: 10.1016/j.radonc.2005.04.017

Source DB:  PubMed          Journal:  Radiother Oncol        ISSN: 0167-8140            Impact factor:   6.280


  3 in total

1.  MRI-detected skull-base invasion: prognostic value and therapeutic implication in intensity-modulated radiotherapy treatment for nasopharyngeal carcinoma.

Authors:  Yi-Kan Cheng; Li-Zhi Liu; Ning Jiang; Dan Yue; Ling-Long Tang; Fan Zhang; Li Lin; Xu Liu; Lei Chen; Jun Ma
Journal:  Strahlenther Onkol       Date:  2014-04-25       Impact factor: 3.621

2.  Health-related quality of life in 640 head and neck cancer survivors after radiotherapy using EORTC QLQ-C30 and QLQ-H&N35 questionnaires.

Authors:  Stephen Wan Leung; Tsair-Fwu Lee; Chih-Yen Chien; Pei-Ju Chao; Wen-Ling Tsai; Fu-Min Fang
Journal:  BMC Cancer       Date:  2011-04-12       Impact factor: 4.430

3.  Comparisons of quality of life for patients with nasopharyngeal carcinoma after treatment with different RT technologies.

Authors:  L Jang-Chun; H Jing-Min; J Yee-Min; L Dai-Wei; C Chang-Ming; L Chun-Shu; H Wen-Yen; S Yu-Fu; L Kuen-Tze; F Chao-Yueh; L Cheng-Hsiang; C Hsing-Lung
Journal:  Acta Otorhinolaryngol Ital       Date:  2014-08       Impact factor: 2.124

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.